Varuby

RSS

Withdrawn

This medicine's authorisation has been withdrawn

rolapitant
MedicineHumanWithdrawn

Lithuanian is available via eTranslation, the European Commission's machine translation service.

Translate to Lithuanian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 23 January 2020 the European Commission withdrew the marketing authorisation for Varuby (rolapitant) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Tesaro Bio Netherlands B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Varuby was granted marketing authorisation in the EU on 20 April 2017 for the prevention of nausea and vomiting. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for Varuby is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (726.36 KB - PDF)

Rodyti

español (ES) (633.54 KB - PDF)

Rodyti

čeština (CS) (705.18 KB - PDF)

Rodyti

dansk (DA) (632.71 KB - PDF)

Rodyti

Deutsch (DE) (634.3 KB - PDF)

Rodyti

eesti (ET) (630.21 KB - PDF)

Rodyti

ελληνικά (EL) (730.25 KB - PDF)

Rodyti

français (FR) (633.57 KB - PDF)

Rodyti

hrvatski (HR) (681.74 KB - PDF)

Rodyti

italiano (IT) (632.87 KB - PDF)

Rodyti

latviešu (LV) (687.32 KB - PDF)

Rodyti

lietuvių (LT) (657.39 KB - PDF)

Rodyti

magyar (HU) (697.73 KB - PDF)

Rodyti

Malti (MT) (800.33 KB - PDF)

Rodyti

Nederlands (NL) (632.83 KB - PDF)

Rodyti

polski (PL) (705.44 KB - PDF)

Rodyti

português (PT) (633.6 KB - PDF)

Rodyti

română (RO) (655.62 KB - PDF)

Rodyti

slovenčina (SK) (703.81 KB - PDF)

Rodyti

slovenščina (SL) (697.48 KB - PDF)

Rodyti

suomi (FI) (632.75 KB - PDF)

Rodyti

svenska (SV) (631.56 KB - PDF)

Rodyti

Product information

български (BG) (1.63 MB - PDF)

Rodyti

español (ES) (986.93 KB - PDF)

Rodyti

čeština (CS) (1.39 MB - PDF)

Rodyti

dansk (DA) (892.42 KB - PDF)

Rodyti

Deutsch (DE) (914.89 KB - PDF)

Rodyti

eesti (ET) (881.8 KB - PDF)

Rodyti

ελληνικά (EL) (1.79 MB - PDF)

Rodyti

français (FR) (901.62 KB - PDF)

Rodyti

hrvatski (HR) (1.12 MB - PDF)

Rodyti

italiano (IT) (902.93 KB - PDF)

Rodyti

latviešu (LV) (1.41 MB - PDF)

Rodyti

lietuvių (LT) (953.91 KB - PDF)

Rodyti

magyar (HU) (1.39 MB - PDF)

Rodyti

Malti (MT) (1.48 MB - PDF)

Rodyti

Nederlands (NL) (891.74 KB - PDF)

Rodyti

polski (PL) (1.44 MB - PDF)

Rodyti

português (PT) (890.31 KB - PDF)

Rodyti

română (RO) (977.61 KB - PDF)

Rodyti

slovenčina (SK) (1.4 MB - PDF)

Rodyti

slovenščina (SL) (1.36 MB - PDF)

Rodyti

suomi (FI) (903 KB - PDF)

Rodyti

svenska (SV) (892.21 KB - PDF)

Rodyti

Íslenska (IS) (898.84 KB - PDF)

Rodyti

norsk (NO) (1023.77 KB - PDF)

Rodyti
Latest procedure affecting product information:T/0015
11/03/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (618.68 KB - PDF)

Rodyti

español (ES) (577.08 KB - PDF)

Rodyti

čeština (CS) (600.04 KB - PDF)

Rodyti

dansk (DA) (574.19 KB - PDF)

Rodyti

Deutsch (DE) (576.81 KB - PDF)

Rodyti

eesti (ET) (574 KB - PDF)

Rodyti

ελληνικά (EL) (618.26 KB - PDF)

Rodyti

français (FR) (573.96 KB - PDF)

Rodyti

hrvatski (HR) (610.25 KB - PDF)

Rodyti

italiano (IT) (573.83 KB - PDF)

Rodyti

latviešu (LV) (607.89 KB - PDF)

Rodyti

lietuvių (LT) (591.92 KB - PDF)

Rodyti

magyar (HU) (599.13 KB - PDF)

Rodyti

Malti (MT) (602.7 KB - PDF)

Rodyti

Nederlands (NL) (573.91 KB - PDF)

Rodyti

polski (PL) (597.52 KB - PDF)

Rodyti

português (PT) (574.02 KB - PDF)

Rodyti

română (RO) (590.38 KB - PDF)

Rodyti

slovenčina (SK) (604.12 KB - PDF)

Rodyti

slovenščina (SL) (595.43 KB - PDF)

Rodyti

suomi (FI) (574.22 KB - PDF)

Rodyti

svenska (SV) (573.78 KB - PDF)

Rodyti

Íslenska (IS) (573.88 KB - PDF)

Rodyti

norsk (NO) (588.52 KB - PDF)

Rodyti

Product details

Name of medicine
Varuby
Active substance
rolapitant
International non-proprietary name (INN) or common name
rolapitant
Therapeutic area (MeSH)
  • Vomiting
  • Nausea
  • Cancer
Anatomical therapeutic chemical (ATC) code
A04AD

Pharmacotherapeutic group

Antiemetics and antinauseants

Therapeutic indication

Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
Varuby is given as part of combination therapy.

Authorisation details

EMA product number
EMEA/H/C/004196
Marketing authorisation holder
TESARO Bio Netherlands B.V.

Joop Geesinkweg 901
1114 AB Amsterdam-Duivendrecht
The Netherlands

Opinion adopted
22/02/2017
Marketing authorisation issued
19/04/2017
Revision
3

Assessment history

This page was last updated on

Share this page